MADOPAR HBS caps. 100/25 100 caps

 

NVS MADOPAR WHAT IS AND WHAT IT IS USED

Madopar 100 mg/25 mg NVS hard prolonged-release capsules are used to treat Parkinson's disease.

 

Madopar NVS 100 mg/25mg udalzhZheno hard capsules contain the active ingredient release levodopa, which is drugs, and benserazide (as hydrochloride), an inhibitor of the decarboxylase and supports the action of levodopa. The two active ingredients work together to treat Parkinson's disease. It is known that in certain parts of the brain in people with this disease are insufficient to contain a substance called dopamine.

 

Signs of the disease are slow motion, rigid muscles, shaking, they can be expressed in many different ways for different patients. In the brain, levodopa is converted into dopamine, thus increasing quantities in the brain to normal levels.

 

Benserazide not very close to the brain, but it serves to prevent the conversion of levodopa to dopamine outside the brain. This helps to reduce side effects in other parts of the body.

 

Madopar 100 mg/25 mg NVS are hard prolonged-release capsules. This means that they remain in the stomach a few hours and the active ingredients are released into the blood.

 

Assuming this medicine, the symptoms of patients suffering from Parkinson's disease may decrease. Madopar 100 mg/25 mg NVS hard capsules extended release does not cure the disease, however, the reason for the lack of dopamine in the brain is not removed.

 

 BEFORE YOU TAKE NVS MADOPAR

 

Do not take Madopar:

 

if you are allergic (hypersensitive) (I levodopa or benserazide or any of the other ingredients of Madopar;

  if you suffer from hormonal disturbance, eg. increased activity of the thyroid gland;

  if you have kidney, liver or heart disease;

  if you suffer from any nervous or mental disorders;

  if you have narrow-angle glaucoma (high pressure in the eye);

  if you have or have had skin cancer (malignant melanoma);

  if you are taking or during the last 14 days you are taking drugs known as inhibitors monoaminooksidzata; (antidepressants)

  if you are pregnant or breast-feeding;

  if you are under 25 years of age (as treatment can affect bone growth).

 

Take special care with Madopar NVS

 

Be sure to tell your doctor:

 

 if you have a surgery because general anesthesia with halothane Madopar intake should be discontinued 12-48 hours before surgery, as can surges in blood pressure and / or arrhythmia. Madopar therapy may be resumed after surgery, follow your doctor's recommendations;

  If you have lung disease;

  if you have a stomach ulcer;

  if you have soft bones;

  if you suffer from asthma, since drugs that you can take for this disease (sympathomimetic drugs) may interact with your medicine;

  if you are taking medication for high blood pressure;

  if you are taking any of the following medications: monoamine oxidase inhibitors (used to treat depressive moods), reserpine (used to treat hypertension), ferrous sulfate (used to treat iron deficiency), metoclopramide (used to treat nausea and vomiting), phenothiazines, thioxanthenes, butyrophenones (all used to treat certain mental disorders, including severe anxiety (agitation), nausea, vomiting, hiccups, amphetamines (drugs that stimulate the nervous system), opiates (eg morphine) - used to relieve pain, any other medicines to treat Parkinson's disease (eg, anticholinergic drugs, amantadine, dopamine agonists, COMT inhibitor) or any medicines that affect the nervous system, including those not prescribed by a physician. This is extremely important as using more than one drug at the same time can strengthen or weaken the effects of the medicine. Patients being treated with this medicine should not take antacids (medicines that neutralize stomach acid) ., please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription;

  In patients with Parkinson's disease treated with dopamine agonists have been reported pathological gambling, increased libido. No association was found between administration of Madopar, which is a dopamine agonist, and these events, but it is recommended to monitor for signs of symptoms such as Madopar is a dopaminergic drug.

Your doctor may want to do some research periodically as blood and urine, checking heart rate and your blood pressure. 

Madopar can affect the results of a study of the level of sugar and other substances in the blood. 

If you are diabetic, you may need to be monitored more frequently blood sugar. 

If your condition has improved during treatment, to restore normal activities gradually. If you exert too much too fast, you risk injury.

 

Pregnancy and lactation

 

Do not take Madopar during pregnancy. You must tell your doctor if you are pregnant, if you are pregnant or plan to become pregnant. Mothers who breastfeed their infants should not take Madopar, because you can not exclude the possibility of the occurrence of musculoskeletal disorders (defects) in children. Ask your doctor or pharmacist before taking any medicine.

 

Driving and operating machinery

 

IMPORTANT

 

Treatment with levodopa is associated with somnolence and very rarely observed excessive daytime somnolence and episodes of sudden sleep onset. Ayuo tayuiva get symptoms, you should tell your doctor and to the resolution of such recurrent episodes and somnolence should refrain from driving or engaging in activities where impaired alertness may put you or others at risk of serious injury (eg operating machines).

 

 HOW TO TAKE NVS MADOPAR

 

Always take Madopar exactly as your doctor tells you. If you're not sure, ask your doctor or pharmacist. Your doctor will prescribe the right dose. Dose your doctor prescribes will depend on your individual symptoms and your response to the drug.

 

Treatment is usually started with a low dose. It gradually increased to find a dose that adequately control your symptoms. During this initial period, your condition may get worse as you find the right dose for you.

 

The usual starting dose is one capsule three times daily for patients who have not previously received levodopa. Patients previously treated with levodopa treatment usually begin by replacing every 100 mg of levodopa with a prolonged-release capsule Madopar 100 mg/25 mg NBS. Then your doctor will adjust the dosage to 2 to 3 days to find the right dose.

 

Madopar 100 mg/25 mg NBS said prolonged-release capsules are taken orally (by mouth). Madopar should be taken preferably 30 minutes before or one hour after eating.

 

Adverse effects from the gastrointestinal tract that can occur mainly in the early stages of treatment, can be controlled to a great extent when Madopar taken with a light snack (eg crackers) or liquids, or when the dose is gradually increased .

 

If you forget to take Madopar

 

If you forget to take a dose, do not have to make up the missed dose by doubling the next. You just continue with the next dose at the time, although in the meantime you can get back some of the symptoms of Parkinson's disease.

Do not change the prescribed dose. If you think that the effect of the drug is very weak or very strong, tell your doctor.

 

If you take an overdose of Madopar

 

When taking too many capsules symptoms and signs are similar to the side effects seen with regular intake of Madopar, but may be more pronounced. Observed cardiac arrhythmia, confusion and insomnia, nausea and vomiting and abnormal involuntary movements. If overdose Madopar NBS, which is a controlled-release, the occurrence of symptoms and signs may be delayed due to delayed absorption of the active ingredients in the stomach.

 

If you take too many capsules or someone else accidentally takes your medicine, contact your doctor, pharmacist or nearest hospital.

 

If you stop taking Madopar

 

Your doctor will advise you when to stop taking the drug. Usually Madopar 100 mg/25 mg NBS said prolonged-release capsules are taken for a long period of time, as it replaces the substance dopamine, which is not produced in sufficient quantities in patients with Parkinson's disease.

 

You must tell your doctor if you want to stop the drug. Although this rarely occurs, abrupt discontinuation can cause serious side effects, eg. reported for neuroleptic malignant like syndrome (hyperpyrexia and muscle stiffness, likely changes in psychological status and serum creatinine phosphokinase), which can be life threatening, after abrupt discontinuation of drugs containing levodopa. To avoid this, your doctor will advise you to stop your treatment. If you have any further questions on the use of this product, ask your doctor or pharmacist.

 

 POSSIBLE SIDE EFFECTS

 

Like all medicines, Madopar can cause side effects, although not everybody gets them.

 

Blood and lymphatic system disorders:

 

In rare cases of hemolytic anemia, transient leukopenia and thrombocytopenia. Therefore, as with any long-term treatment with medicines containing levodopa, your doctor will monitor your blood counts and liver and renal function.

 

Metabolism and nutrition disorders:

 

Reported anorexia.

 

Psychiatric disorders:

 

Depression is common in patients with Parkinson's disease, including those treated with levodopa. May occur: agitation, anxiety, insomnia, hallucinations, seeing people or objects 6aobrazhaemi, temporary disorientation, especially in elderly patients and patients with a history of such disorders.

 

Nervous system disorders:

 

Some people may experience a loss or change in taste. In later stages of treatment may occur uncontrolled, abnormal movements of the arms, legs, face and tongue. These effects can be overcome or become manageable through dose reduction. Once the drug is taken for many years, may occur, and changes in response to treatment. These include episodes when sudden movements are difficult (episodes of "freezing"), return of symptoms of the disease before the next dose of the drug (worsening at the end of dose) or sudden changes of periods of good symptom control ("Off" periods) to periods with poor control of symptoms ("Off" periods). they can usually be overcome or become tolerable by reducing daily doses or more often take lower doses. administration of Madopar is associated with somnolence and very rarely has been associated with excessive daytime sleepiness and episodes of sudden sleep onset.

 

Cardiac disorders:

 

May occur changes in heart rhythm.

 

Vascular disorders:

 

There are isolated reports of blood pressure changes.

 

Gastrointestinal disorders:

 

During treatment with Madopar reported nausea, vomiting and diarrhea. Adverse gastrointestinal effects can occur mainly in the early stages of treatment may be controlled largely by Madopar be taken with food or liquid, or slowly increase.

 

Skin and subcutaneous tissue disorders:

 

In rare cases, allergic skin reactions occur, such as itching and rash.

 

Investigations

 

May occur transient increase in liver transaminases and alkaline phosphatase. Have been reported to increase in gamma-glutamine transferase. During treatment with Madopar is observed increases in blood urea. The color of urine can change, usually yield a red tint, which darkens when urine stays. These changes are the result of the drug and are not cause for concern.

 

If any of the side effects gets serious, or you notice other effects not listed in this leaflet, please tell your doctor or pharmacist.

 

 HOW TO STORE NVS MADOPAR

 

 Keep out of reach of children.

  Do not store above 25 ° C.

  Store in the original package to protect from moisture.

  Keep the bottle tightly closed.

  Do not use Madopar NVS after the expiry date (EXP) which is stated on the carton. The expiry date refers to the last day of that month.

  Back rest of medicine at the pharmacy. Keep it only if your doctor has told you.

 

 ADDITIONAL INFORMATION

 

What Madopar NVS

  The active substances are: levodopa and benserazide.

 The other ingredients are calcium hydrogen phosphate anhydrous; метилхидроксипропилцелулоза, hydrogenated vegetable oil, mannitol, talc, povidone, magnesium stearate. 

Each capsule contains 100 mg levodopa and 25 mg benserazide hydrochloride form.